Journal of Periodontal and Implant Science

Korean Academy of Periodontology (대한치주과학회)
권호 표지
DOI QR코드

DOI QR Code

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health

  • Received : 2013.06.20
  • Accepted : 2013.09.27
  • Published : 2013.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system plays a significant role in osteoclastogenesis, activation of osteoclasts, and regulation of bone resorption. This study aimed to evaluate the use of the salivary soluble RANKL (sRANKL)/OPG ratio as a diagnostic marker for periodontitis in nonsmokers. Methods: Twenty-five patients with chronic periodontitis and 25 individuals with a healthy periodontium were enrolled in this study. Samples containing 5 mL of unstimulated saliva were obtained from each subject. Salivary sRANKL and OPG concentrations were determined using a standard enzyme-linked immunosorbent assay. Statistical analysis was performed using SPSS ver. 18.0. Results: The levels of sRANKL and OPG were detectable in all of the samples. Positive relationships were found between the plaque index and clinical attachment level and both the salivary concentration of sRANKL and the salivary sRANKL/OPG ratio (P<0.05). The salivary concentration of sRANKL and the sRANKL/OPG ratio were significantly higher in the periodontitis group than in the healthy group (P=0.004 and P=0.001, respectively). In contrast, the OPG concentration showed no significant differences between the groups (P=0.455). Conclusions: These findings suggest that the salivary sRANKL/OPG ratio may be helpful in the screening and diagnosis of periodontitis. However, longitudinal studies with larger populations are needed to confirm these results.

Keywords

References

  1. Genco RJ. Current view of risk factors for periodontal diseases. J Periodontol 1996;67(10 Suppl):1041-9. https://doi.org/10.1902/jop.1996.67.10s.1041
  2. Giannobile WV, Beikler T, Kinney JS, Ramseier CA, Morelli T, Wong DT. Saliva as a diagnostic tool for periodontal disease: current state and future directions. Periodontol 2000 2009;50:52-64. https://doi.org/10.1111/j.1600-0757.2008.00288.x
  3. Sexton WM, Lin Y, Kryscio RJ, Dawson DR 3rd, Ebersole JL, Miller CS. Salivary biomarkers of periodontal disease in response to treatment. J Clin Periodontol 2011;38:434-41. https://doi.org/10.1111/j.1600-051X.2011.01706.x
  4. Kaufman E, Lamster IB. Analysis of saliva for periodontal diagnosis: a review. J Clin Periodontol 2000;27:453-65. https://doi.org/10.1034/j.1600-051x.2000.027007453.x
  5. Buduneli N, Kinane DF. Host-derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis. J Clin Periodontol 2011;38 Suppl 11:85-105. https://doi.org/10.1111/j.1600-051X.2010.01670.x
  6. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57. https://doi.org/10.1210/edrv.20.3.0367
  7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602. https://doi.org/10.1073/pnas.95.7.3597
  8. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res 2000;15:1459-66. https://doi.org/10.1359/jbmr.2000.15.8.1459
  9. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-50. https://doi.org/10.1006/bbrc.1999.1623
  10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76. https://doi.org/10.1016/S0092-8674(00)81569-X
  11. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23. https://doi.org/10.1038/16852
  12. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42. https://doi.org/10.1038/nature01658
  13. Vega D, Maalouf NM, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007;92:4514-21. https://doi.org/10.1210/jc.2007-0646
  14. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38:380-7. https://doi.org/10.1034/j.1600-0765.2003.00615.x
  15. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-9. https://doi.org/10.1177/154405910408300216
  16. Vernal R, Chaparro A, Graumann R, Puente J, Valenzuela MA, Gamonal J. Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004;75:1586-91. https://doi.org/10.1902/jop.2004.75.12.1586
  17. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 2007;34:370-6. https://doi.org/10.1111/j.1600-051X.2007.01061.x
  18. Frodge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol 2008;79:1913-9. https://doi.org/10.1902/jop.2008.080070
  19. Miller CS, King CP Jr, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: a cross-sectional study. J Am Dent Assoc 2006;137:322-9. https://doi.org/10.14219/jada.archive.2006.0181
  20. Costa PP, Trevisan GL, Macedo GO, Palioto DB, Souza SL, Grisi MF, et al. Salivary interleukin-6, matrix metalloproteinase-8, and osteoprotegerin in patients with periodontitis and diabetes. J Periodontol 2010;81:384-91. https://doi.org/10.1902/jop.2009.090510
  21. Al-Sabbagh M, Alladah A, Lin Y, Kryscio RJ, Thomas MV, Ebersole JL, et al. Bone remodeling-associated salivary biomarker MIP-$1{\alpha}$ distinguishes periodontal disease from health. J Periodontal Res 2012;47:389-95. https://doi.org/10.1111/j.1600-0765.2011.01445.x
  22. Tobon-Arroyave SI, Isaza-Guzman DM, Restrepo-Cadavid EM, Zapata-Molina SM, Martinez-Pabon MC. Association of salivary levels of the bone remodelling regulators sRANKL and OPG with periodontal clinical status. J Clin Periodontol 2012;39:1132-40. https://doi.org/10.1111/jcpe.12012
  23. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6. https://doi.org/10.1902/annals.1999.4.1.1
  24. Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condtion. Acta Odontol Scand 1964;22:121-35. https://doi.org/10.3109/00016356408993968
  25. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J 1975;25:229-35.
  26. Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993;694:72-7. https://doi.org/10.1111/j.1749-6632.1993.tb18343.x
  27. Kinney JS, Ramseier CA, Giannobile WV. Oral fluid-based biomarkers of alveolar bone loss in periodontitis. Ann N Y Acad Sci 2007;1098:230-51. https://doi.org/10.1196/annals.1384.028
  28. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J Periodontal Res 2005;40:287-93. https://doi.org/10.1111/j.1600-0765.2005.00814.x
  29. Buduneli N, Biyikoglu B, Sherrabeh S, Lappin DF. Saliva concentrations of RANKL and osteoprotegerin in smoker versus non-smoker chronic periodontitis patients. J Clin Periodontol 2008;35:846-52. https://doi.org/10.1111/j.1600-051X.2008.01310.x
  30. Belibasakis GN, Bostanci N. The RANKL-OPG system in clinical periodontology. J Clin Periodontol 2012;39:239-48. https://doi.org/10.1111/j.1600-051X.2011.01810.x

Cited by

  1. Effect of Periodontal Surgery on Osteoprotegerin Levels in Gingival Crevicular Fluid, Saliva, and Gingival Tissues of Chronic Periodontitis Patients vol.2015, pp.None, 2013, https://doi.org/10.1155/2015/341259
  2. Salivary cytokines as biomarkers of periodontal diseases vol.70, pp.1, 2016, https://doi.org/10.1111/prd.12117
  3. Assessment of Salivary Levels of RANKL and OPG in Aggressive versus Chronic Periodontitis vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/6195258